Score Overview
Explore the 2021 public Archive ranking →
Where Edwards Lifesciences Corp has ranked, year by year
Showing all available years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- EW
2005: 75.3% · 2021: 18.8% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 88.08 | — |
1 Year2025-09-29 | $ 77.19 | 14.11% |
5 Years2021-09-29 | $ 113.52 | -22.41% |
10 Years2016-09-29 | $ 39.75 | 121.57% |
20 Years2006-09-29 | $ 3.88 | 22x |
All Time2000-03-27 | $ 1.38 | 64x |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | All Time2000-03-27 |
|---|---|---|---|---|---|---|
| Price | $ 88.08 | $ 77.19 | $ 113.52 | $ 39.75 | $ 3.88 | $ 1.38 |
| Return | — | 14.11% | -22.41% | 121.57% | 22x | 64x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 6.51B | $ 1.00B | |
| 2025 | $ 6.06B | $ 1.07B | $ 4.22B |
| 2024 | $ 5.43B | $ 4.17B | $ 3.97B |
| 2023 | $ 6.00B | $ 1.40B | $ 1.63B |
| 2022 | $ 5.38B | $ 1.52B | $ 1.21B |
| 2021 | $ 5.23B | $ 1.50B | $ 1.46B |
| 2020 | $ 4.38B | $ 823M | $ 1.40B |
| 2019 | $ 4.34B | $ 1.04B | $ 1.51B |
| 2018 | $ 3.72B | $ 722M | $ 956M |
| 2017 | $ 3.43B | $ 622M | $ 1.33B |
| 2016 | $ 2.96B | $ 569M | $ 1.27B |
| 2015 | $ 2.49B | $ 494M | $ 1.22B |
| 2014 | $ 2.32B | $ 811M | $ 1.43B |
| 2013 | $ 2.04B | $ 391M | $ 936M |
| 2012 | $ 1.89B | $ 293M | $ 521M |
| 2011 | $ 1.67B | $ 236M | $ 450M |
| 2010 | $ 1.44B | $ 218M | $ 396M |
| 2009 | $ 1.32B | $ 229M | $ 334M |
| 2008 | $ 1.23B | $ 128M | $ 226M |
| 2007 | $ 1.09B | $ 113M | $ 191M |
| 2006 | $ 1.03B | $ 130M | $ 182M |
| 2005 | $ 997M | $ 79M | $ 178M |
| 2004 | $ 931M | $ 1M | $ 48M |
| 2003 | $ 860M | $ 79M | $ 61M |
| 2002 | $ 704M | $ 55M | $ 34M |
| 2001 | $ 692M | -$ 12M | $ 48M |
| IPO2000 | $ 804M | -$ 272M | $ 28M |
Edwards Lifesciences Corp fundamental performance
Between 2015 and 2025, revenue grew from $ 2.49B to $ 6.06B and net income grew from $ 494M to $ 1.07B. Revenue increased in 9 of those 10 years; net income in 6.
Between 2005 and 2025, revenue grew from $ 997M to $ 6.06B and net income grew from $ 79M to $ 1.07B. Revenue increased in 19 of those 20 years; net income in 13.
Edwards Lifesciences Corp currently holds a 20-year HDB Score of 8.0 out of 10. How the HDB Score is calculated.
Membership
Continue EW’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
Explore other companies
Mettler-Toledo International IncMTD· revenue grew in 85% of years
UFP Technologies IncUFPT· revenue grew in 80% of years
West Pharmaceutical Services IncWST· revenue grew in 90% of years
UnitedHealth Group IncorporatedUNH· revenue grew in 100% of years
Regeneron Pharmaceuticals IncREGN· revenue grew in 90% of years
